New drug aims to tame lupus flares

NCT ID NCT06535412

Recruiting now Disease control Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests an experimental drug called IMC-002 (also known as IMM0306) in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial compares the drug against a placebo, both given alongside standard care, to see if it can reduce disease activity and improve symptoms. About 218 participants will receive either intravenous or subcutaneous injections of the drug or a placebo. The goal is to find a safer and more effective way to manage lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMC-002 (also called IMM0306)
What this could lead to: If successful, this could provide a new treatment option for people with active lupus, helping to control the disease and reduce flares.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.